# Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Participants With Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced or Metastatic Breast Cancer

> **NCT02964507** · PHASE1 · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 124 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** GSK525762
- **DRUG:** Placebo
- **DRUG:** Fulvestrant

## Key facts

- **NCT ID:** NCT02964507
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-09-26
- **Primary completion:** 2020-09-29
- **Final completion:** 2021-07-19
- **Target enrollment:** 124 (ACTUAL)
- **Why stopped:** This study has been terminated due to meeting protocol defined futility.
- **Last updated:** 2024-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02964507

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02964507, "Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Participants With Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced or Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02964507. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*